Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.

Katherine R TuttleAdeera LevinMasaomi NangakuTakashi KadowakiRajiv AgarwalSibylle J HauskeAmelie ElsäßerIvana RitterDominik SteublChristoph WannerDavid C Wheeler

Published in: Diabetes care (2022)

Use of empagliflozin in patients with type 2 diabetes and advanced CKD raised no new safety concerns and may have beneficial effects on the development of hyperkalemia and edema.

Keyphrases

chronic kidney disease
clinical trial
end stage renal disease
placebo controlled
phase iii
double blind
phase ii
study protocol
randomized controlled trial